Author of

• 10743

  +

  P1.10 - Poster Session 1 - Chemotherapy (ID 204)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 10752

    +

    P1.10-009 - Comparison of Chemotherapy Effect between Cisplatin-Etoposide and Cisplatin-Docetaxel in 2-year Survival Rate and Progression Free Survival Rate of Advanced Non-Small Cell Lung Cancer Patients (ID 730)

    09:30 - 09:30  |  Author(s): N. Sutandyo
    • Abstract

    Background
    One of the therapies for the advanced Non-Small Cell Lung Cancer (NSCLC) is chemotherapy. The success therapy is measured by 1-year survival, 2-year survival and progression free survival (PFS). The success is influenced by many factors such as resistant to the cytostatic, dosage, administer intensity, chemotherapy regiment, type of histology, stage, performance status, comorbidity and socioeconomics. In Indonesia, chemotherapy expense is one of the problem for the treatment which docetaxel is much expensive than etoposide. Purposes this study are to determine the survival and PFS difference between the NSCLC patients that were treated with Cisplatin-Etoposide (EC) against Cisplatin-Docetaxel (DC).

    Methods
    The study was using the retrospective cohort study with survival analysis. The patients that included to this study were the advanced NSC Lung Cancer (at least stadium IIIa) who came to Dharmais Cancer Hospital and Cipto Mangukusumo Hospital during January 2006 until December 2010 for their first chemotherapy until finished the cycle (6 times) and had 2-year monitoring. Data was analyzed by SPSS 16.0 by cox regression analysis, and featured on the Kaplan Meier Curve.

    Results
    Fifty five patients were using EC and the other 55 patients were using DC. There were significant difference in survival: 1-year survival of EC group was 30.9% and DC group was 47.3% (p 0.030); 2- year survival of EC group was 0% and DC group was 5.5% (p 0.003); median time survival of EC group was 27 weeks and DC group was 38 weeks (p < 0.016). Compared to DC group, chemotherapy in EC group increased the death risk (HR 1.684; CI 95% 1.010-2.810). Moreover, twenty four weeks PFS in EC group (54.5%) was better than DC group (32.7%) with p < 0.022.

    Conclusion
    The survival and PFS with cisplatin-docexatel is better compare to cisplatin-etoposid. But we can still give cisplatin etoposide if patients have financial problem.